Please assess the completion status of the following clinical trial:

Trial Title: Study of UB-312 in Healthy Participants and Parkinson's Disease Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 40 to 85 years old, inclusive at screening~* Expected to be able to undergo all study procedures~* Other inclusion criteria apply~For Part B only:~* A diagnosis of PD, confirmed by a neurologist~* Hoehn \&Yahr Stage ≤ III at Screening~* Stable treatment of permitted antiparkinsonian medications from 30 days prior to first study drug administration or 60 days for MAO-B inhibitors, and expected to remain stable throughout the study~Exclusion Criteria:~* Clinically significant abnormalities, as judged by the investigator~* History of medical, neurological or psychiatric conditions which in the opinion of the investigator may compromise participant's safety or scientific value of the study~* Acute or chronic infection as judged by the investigator, for positive human immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis B virus (HBV)~* History or evidence of an autoimmune disorder~* History of anergy.~* Participated/participating in any clinical trial with monoclonal antibodies or vaccines directed at aSyn~* Other exclusion criteria apply~For Part B only:~* Other known or suspected cause of Parkinsonism other than idiopathic PD~* History or evidence at Screening of PD-related freezing episodes, falls, or orthostatic hypotension~* Dopamine transporter single-photon emission computerized tomography scan (DaTscan) inconsistent with dopamine transporter deficit.~* Clinically significant neurological disease other than PD

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- UB-312 40 mcg (Type: EXPERIMENTAL): UB-312 40 mcg by intramuscular injection at Weeks 1, 5 and 13
- UB-312 100 mcg (Type: EXPERIMENTAL): UB-312 100 mcg by intramuscular injection at Weeks 1, 5 and 13
- UB-312 40/300 mcg (Type: EXPERIMENTAL): UB-312 40 mcg at Week 1 and 300 mcg at Weeks 5 and 13 by intramuscular injection
- UB-312 300 mcg (Type: EXPERIMENTAL): UB-312 300 mcg by intramuscular injection at Weeks 1, 5 and 13
- UB-312 40/1000 mcg (Type: EXPERIMENTAL): UB-312 40 mcg at Week 1 and 1000 mcg at Weeks 5 and 13 by intramuscular injection
- UB-312 1000 mcg (Type: EXPERIMENTAL): UB-312 1000 mcg by intramuscular injection at Weeks 1, 5 and 13
- UB-312 2000 mcg (Type: EXPERIMENTAL): UB-312 2000 mcg by intramuscular injection at Weeks 1, 5 and 13
- Placebo (Type: PLACEBO_COMPARATOR): Placebo by intramuscular injection at Weeks 1, 5 and 13
- UB-312 300/100 mcg (Type: EXPERIMENTAL): UB-312 300 mcg at Week 1 and 100 mcg at Weeks 5 and 13 by intramuscular injection

Based on this trial design, predict the completion outcome and termination type (if applicable).